Search Tips
of 1 Next >
Results Found: 3
  • SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018): MSK-IMPACT sequencing of 86 patients with HER2- and HER3-mutant cancers

    Description

    This dataset contains summary data visualizations and clinical data from a broad sampling of HER2- and HER3-mutant tumors. The data was generated utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, Amplification Status, Best objective response rate, Bubble...

    Subject
    Breast Neoplasms
    Carcinoma, Hepatocellular
    Carcinoma, Non-Small-Cell Lung
    Carcinoma, Renal Cell
    Colorectal Neoplasms
    DNA Mutational Analysis
    Endometrial Neoplasms
    Esophageal Neoplasms
    Genes, erbB
    Genes, erbB-2
    Melanoma
    Ovarian Neoplasms
    Pancreatic Neoplasms
    Salivary Gland Neoplasms
    Sarcoma
    Skin Neoplasms
    Urinary Bladder Neoplasms
    Uterine Cervical Neoplasms
    Access Rights
    Free to All
  • Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

    Authors
    Burman, Bharat
    Jain, Swati
    Fitzgerald, Conall W.R.
    Sherman, Eric J.
    22 more author(s)...
    Description

    Description from Zenodo: "This is a de-identified dataset accompanying the Nature Medicine publication titled "Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial", by Vos et al. (DOI: https://doi.org/10.1038/s41591-023-02518-x). It contains the clinical features and processed data of 64 patients with salivary gland cancer, treated with nivolumab and ipilimumab immunotherapy....

    Subject
    Clinical Trial, Phase II
    Immunotherapy
    Ipilimumab
    Nivolumab
    Salivary Gland Neoplasms
    Access Rights
    Free to All
  • Determinants of Response to Nivolumab plus Ipilimumab in a Phase II Trial of Advanced Salivary Gland Cancer Patients

    Description

    Description from BioProject: "Salivary gland cancers (SGCs) are rare, aggressive cancers that lack effective treatments in the metastatic setting. We report the clinical results and immunogenomic correlates of response from a phase II trial evaluating nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) in metastatic SGC patients."

    Subject
    Clinical Trial, Phase II
    Exome Sequencing
    Ipilimumab
    Nivolumab
    RNA-Seq
    Salivary Gland Neoplasms
    Access Rights
    Free to All